This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan
by Zacks Equity Research
The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.
What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.
Top Ranked Momentum Stocks to Buy for February 4th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 4th
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy
by Zacks Equity Research
Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
Top Ranked Momentum Stocks to Buy for January 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 24th
Are You Looking for a Top Momentum Pick? Why Xenon Pharmaceuticals (XENE) is a Great Choice
by Zacks Equity Research
Does Xenon Pharmaceuticals (XENE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Xenon Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Xenon Pharmaceuticals.
Xenon Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Xenon Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
4 Healthcare Stocks Thriving on Venture Capital Funding
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
by Swarup Gupta
Biotech stocks are largely resilient to trade related disruptions.
Teva/Xenon Nerve Pain Candidate Fails in Phase II Study
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that a mid-stage study evaluating their pipeline candidate, topical TV-45070 for post-herpetic neuralgia (PNH) did not meet the primary endpoint.
3 of the Best & Worst Performing Drug Stocks of Q1
by Arpita Dutt
Here is a look at 3 of the best and worst-performing drug stocks in the first quarter of 2017.